Treatment
Lebrikizumab clinical trials
We’re tracking 7 recruiting studies that include Lebrikizumab, each written for real people, not researchers, below.
Recruiting studies
- NCT07542483RecruitingPhase 3
Lebrikizumab for nummular eczema in adults
This study tests whether lebrikizumab, a new injection, can reduce nummular eczema (coin-shaped eczema patches) in adults whose condition hasn't improved with topical steroid creams. It's designed to help people with moderate-to-severe nummular eczema who need a stronger treatment option.
Freiburg im BreisgauAges 18 years+ - NCT05735483Enrolling by invitationPhase 3
Long-term lebrikizumab study for moderate to severe eczema
This Phase 3 trial studies whether lebrikizumab is safe and continues to work over the long term for children and teens with moderate-to-severe atopic dermatitis (eczema). It’s meant for people who already finished a related earlier study and can safely continue.
Birmingham, AlabamaAges 6 months–18 years - NCT07807228Recruiting
Skin microbiome changes with lebrikizumab for eczema
This study looks at how lebrikizumab, a biologic medicine for atopic dermatitis (eczema), affects the skin's microbiome (the natural community of microorganisms on your skin). It aims to see if changes in the skin's microbiome are linked to treatment response.
CopenhagenAges 18 years+ - NCT07471932RecruitingPhase 1
Testing a new skin medicine in healthy adults
This trial is testing a new study drug called LAD106 to see if it is safe in healthy adults. It helps researchers learn how the drug works in the body before moving on to patients with a specific condition.
LeidenAges 18–45 - NCT06815380Recruiting
Study on lebrikizumab for people with atopic dermatitis
This study looks at how lebrikizumab (Ebglyss) affects daily life and skin symptoms in adults with moderate-to-severe eczema. You may join if your doctor has prescribed this medication as part of your regular care.
Aarhus, DenmarkAges 18 years+ - NCT03358693Recruiting
Study of inflammation patterns in chronic skin diseases
This study looks at molecular (body-level) signatures in people with chronic inflammatory skin conditions. You may help researchers understand what drives inflammation, while receiving standard (already approved) systemic treatment through routine care.
KielAges Any age - NCT06338995RecruitingPhase 3
Lebrikizumab for nasal polyps and sinusitis
This trial tests a new injectable medicine (lebrikizumab) for people with chronic sinusitis and nasal polyps that steroid treatments haven't controlled. It aims to reduce polyp size and improve breathing, smell, and congestion.
Birmingham, AlabamaAges 12 years+
What Lebrikizumab is being studied for
Conditions with recruiting Lebrikizumab studies.
Common questions
- Are there clinical trials studying Lebrikizumab?
- Yes. Clin2 currently lists 7 recruiting studies that include Lebrikizumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Lebrikizumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Lebrikizumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Lebrikizumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.